Tyrvaya, Byooviz top ophthalmology FDA approval news in 2021
Click Here to Manage Email Alerts
The most-read FDA approval stories of 2021 include Tyrvaya nasal spray and Byooviz, the first ophthalmology biosimilar to receive FDA approval.
Read more about the FDA approvals below.
Tyrvaya nasal spray receives FDA approval for treatment of dry eye disease
The FDA approved Tyrvaya nasal spray for the treatment of signs and symptoms of dry eye disease, according to a press release from Oyster Point Pharma. Read more.
FDA approves Byooviz, first ophthalmology biosimilar
The FDA has approved Byooviz as a biosimilar to Lucentis for the treatment of some retinal diseases and conditions, including wet age-related macular degeneration, according to a press release from Samsung Bioepis and Biogen. Read more.
New therapy for wet AMD gains FDA approval
Genentech announced the FDA has approved ranibizumab 100 mg/mL injection for wet age-related macular degeneration in patients who previously responded to at least two anti-VEGF injections. Read more.
FDA approves IPL device for treatment of dry eye disease signs
The FDA has granted de novo authorization to Lumenis for its intense pulsed light device for the management of dry eye disease signs due to meibomian gland dysfunction. Read more.
FDA approves Vuity, first eye drop to treat presbyopia
Allergan, an AbbVie company, announced the FDA approval of the eye drop, Vuity, for the treatment of presbyopia. Read more.
Collapse
Healio Coverage
Read more about
Click Here to Manage Email Alerts